AGTR2

AGTR2 is an X-linked G-protein-coupled receptor for angiotensin II that functions in both neurodevelopment and cardiovascular homeostasis, broadly acting as a counter-regulatory receptor that opposes AT1R (AGTR1)-driven oxidative and inflammatory signaling (PMID:12089445, PMID:18096165). In the brain, loss-of-function frameshift and missense mutations in AGTR2 cause X-linked intellectual disability, and Agtr2-knockout mice display impaired spatial memory together with abnormal dendritic spine morphology linked to dysregulation of microtubule-associated genes, establishing AGTR2 in a pathway controlling spine structure and cognition (PMID:12089445, PMID:14598163, PMID:19501643). Mechanistically in neurons, AGTR2 forms heterodimers with the neurotrophin receptor TRKB and, upon angiotensin II stimulation, increases surface TRKB and its coupling to the SRC-family kinase FYN, transactivating TRKB signaling (PMID:29550391). In cardiovascular tissue, AGTR2 overexpression suppresses atherogenesis, NADPH oxidase, nitrotyrosine, NF-κB and p38/p44/42 MAPK signaling and collagen accumulation while restoring eNOS, HO-1, Akt-1 phosphorylation and superoxide dismutase activity (PMID:18096165, PMID:18037370). Cardiac Agtr2 expression is regulated by glucocorticoid receptor binding to glucocorticoid response elements in its promoter, a mechanism through which maternal high-fat diet programs cardiac ischemic vulnerability (PMID:26157067), and a non-coding enhancer variant that reduces AGTR2 expression in uterus via allele-specific CEBPB/HOXA10 binding increases preterm birth risk (PMID:37455310).

1. 1995 High

   Establishing the chromosomal location of AGTR2 was the prerequisite for connecting the gene to X-linked phenotypes.

   Evidence Interspecific backcross linkage mapping in mouse and FISH in human

   PMID:7606933 PMID:8586443

   Open questions at the time

   • Mapping alone does not assign function
   • No link to disease established at this stage
2. 2002 High

   Identifying loss-of-function mutations and absent expression in patients answered whether AGTR2 is required for normal cognition, linking the receptor to brain development.

   Evidence Mutation screening of 590 male MR patients and an X;7 translocation case

   PMID:12089445

   Open questions at the time

   • Did not define the cellular mechanism of cognitive impairment
   • No functional assay of mutant receptors
3. 2003 Medium

   Additional independent missense mutations confirmed the AGTR2-intellectual disability association in a separate cohort.

   Evidence Mutation screening of 57 Finnish male MR patients

   PMID:14598163

   Open questions at the time

   • No functional characterization of G21V/I53F
   • Single screening method
4. 2007 Medium

   Gain-of-function overexpression in atherosclerotic mice answered what protective cardiovascular role AGTR2 plays, defining it as a counter-regulatory receptor opposing AT1R-driven oxidative, inflammatory and fibrotic signaling.

   Evidence AAV-mediated AGTR2 overexpression in LDLR-KO mice with IHC, Western blot, collagen and enzyme assays

   PMID:18037370 PMID:18096165

   Open questions at the time

   • Overexpression may not reflect endogenous receptor levels
   • Direct G-protein coupling not resolved
   • Single lab
5. 2009 Medium

   A knockout model linked AGTR2 loss to a concrete neuronal phenotype, showing impaired spatial memory and abnormal dendritic spines tied to microtubule-related gene expression.

   Evidence Agtr2-/y mice with behavioral testing, microarray and qRT-PCR

   PMID:19501643

   Open questions at the time

   • Causal chain from receptor to spine morphology unresolved
   • Microtubule genes correlative, not validated targets
   • Single lab
6. 2015 Medium

   ChIP and pharmacologic rescue revealed how AGTR2 cardiac expression is transcriptionally controlled and how it mediates developmental programming of ischemic vulnerability.

   Evidence Maternal HFD rat model with ChIP of GR on the Agtr2 promoter, expression assays and PD123319 ischemia-reperfusion rescue

   PMID:26157067

   Open questions at the time

   • Mechanism downstream of AGTR2 in ischemia not defined
   • Sex-specificity mechanism unexplained
   • Single lab
7. 2018 Medium

   Co-IP and surface receptor assays answered how AGTR2 signals in neurons, demonstrating heterodimerization with TRKB and FYN-mediated transactivation.

   Evidence Co-IP of GFP-AGTR2 with TRKB in MG87 cells, surface TRKB quantification in cortical cells, PD123319 antagonism

   PMID:29550391

   Open questions at the time

   • Stoichiometry of the heterodimer unknown
   • Link between TRKB transactivation and spine phenotype untested
   • Single lab
8. 2018 Medium

   Genetic and pharmacologic loss-of-function established a pathogenic role for AGTR2 signaling in cystic fibrosis pulmonary disease.

   Evidence AGTR2-KO crossed with two CF mouse models plus chronic PD123319, with pulmonary function readouts

   PMID:29937318

   Open questions at the time

   • Downstream mediators in lung not defined
   • Cell type responsible unidentified
9. 2023 Medium

   Functional dissection of a non-coding variant answered how AGTR2 expression is regulated in uterus and links reduced expression to preterm birth.

   Evidence Reporter/enhancer assays, allele-specific CEBPB/HOXA10 binding and GTEx uterine eQTL analysis

   PMID:37455310

   Open questions at the time

   • Causal pathway from uterine AGTR2 to parturition not established
   • TF binding not validated in vivo

• The structural basis and full downstream signaling network of AGTR2 across its neuronal and cardiovascular roles remain incompletely defined.
• No experimental structure of agonist-bound AGTR2
• Mechanism connecting TRKB transactivation to dendritic spine and cognition unproven
• G-protein/effector coupling not directly mapped